Synthesis and development of new 2-substituted 1-[3-(4-arylpiperazin-1-yl) propyl]-pyrrolidin-2-one derivatives with antiarrhythmic, hypotensive, and α-adrenolytic activity

Farmaco

Volumn 60, Issue 10, 2005, Pages 793-803

  Malawska, Barbara ^a   Kulig, Katarzyna ^a   Gippert, Annika ^a   Filipek, Barbara ^a   Sapa, Jacek ^a   Macia̧g, Dorota ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Adrenoceptor blocking activity; Antiarrhythmic; Hypotensive; Molecular modelling; N (4 Arylpiperazin 1 yl)propylpyrrolidin 2 one derivatives

Indexed keywords

1 [2 (N 2 METHYLETHYLCARBAMOYLOXY) 3 (4 PHENYLPIPERAZIN 1 YL)PROPYL]PYRROLIDIN 2 ONE; 1 [2 (N 2 METHYLETHYLCARBAMOYLOXY) 3 [4 (2 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 (N 2 METHYLETHYLCARBAMOYLOXY) 3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL)]PROPYL]PYRROLIDIN 2 ONE; 1 [2 (N BUTYLCARBAMOYLOXY) 3 (4 PHENYLPIPERAZIN 1 YL)PROPYL]PYRROLIDIN 2 ONE; 1 [2 (N BUTYLCARBAMOYLOXY) 3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 (N ETHYLCARBAMOYLOXY) 3 (4 PHENYLPIPERAZIN 1 YL)PROPYL]PYRROLIDIN 2 ONE; 1 [2 (N ETHYLCARBAMOYLOXY) 3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 (N PROPYLCARBAMOYLOXY) 3 (4 PHENYLPIPERAZIN 1 YL)PROPYL]PYRROLIDIN 2 ONE; 1 [2 (N PROPYLCARBAMOYLOXY) 3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HYPERTENSION; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PHARMACOPHORE; PROPHYLAXIS; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ACUTE TOXICITY TESTS; ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ARRHYTHMIA; BLOOD PRESSURE; HYPERTENSION; MALE; MICE; MOLECULAR STRUCTURE; PYRROLIDINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA;

EID: 26944453588     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2005.08.002     Document Type: Article

References (38)

1. J.P. Hielbe, and R.R. Ruffolo The use of α-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview Pharmacol. Res. 33 1996 145 160
2. B. Kenny, S. Ballad, J. Blagg, and D. Fox Pharmacological options in the treatment of benign prostatic hyperplasia J. Med. Chem. 40 1997 1293 1315
3. 1a adrenergic receptor antagonists Ann. Rep. Med. Chem. 35 2000 221 230
4. 1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH) J. Med. Chem. 44 2001 1971 1985
5. D.J. Sheridan, P.A. Penkoske, B.E. Sobel, and P.B. Corr Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats J. Clin. Invest. 65 1980 161 171
6. + currents via different signaling pathways in canine ventricular myocytes J. Biol. Chem. 276 2001 40811 40816
7. P.B. Corr, J.A. Shayman, J.B. Kramer, and R.J. Kipnis Increased alpha-adrenergic receptors in ischemic cat myocardium. A potential mediator of electrophysiological derangements J. Clin. Invest. 67 1981 1232 1236
8. B. Malawska, M. Gorczyca, and B. Filipek Synthesis, physicochemical and preliminary pharmacological properties of N-[β-hydroxy-γ-(N- phenylpiperazinepropyl)]-2-pyrrolidinone Pol. J. Pharmacol. Pharm. 44 1992 561 574
9. B. Filipek, J. Sapa, B. Malawska, K. Kulig, and L. Antkiewicz-Michaluk Synthesis, antiarrhythmic, antihypertensive, and α-adrenoceptor blocking activity of novel 1-[(2-hydroxy-3-amino)]-propylpyrrolidin-2-one derivatives Arch. Pharm. Pharm. Med. Chem. 330 1997 225 231
10. B. Malawska, K. Kulig, B. Filipek, J. Sapa, D. Macia̧g, M. Zygmunt, and L. Antkiewicz-Michaluk Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-substituted pyrrolidin-2-one and pyrrolidine derivatives with adrenolytic activity Eur. J. Med. Chem. 37 2002 183 195
11. L. Beneš, and M. Ščasná Substituted 1-ethyl-2-(alkylamino)ethyl esters of phenylcarbamic acids with antiarrhythmic and local anesthetic activity and method of their preparation 1992 Czech [8 pp. CS 275225 CA 119 (1993) 225701e]
12. E.G. Chalina, L. Chakarova, and D.T. Staneva Synthesis, antiarrhythmic and hypotensive activity of some novel 1,3-disubstituted ureas and phenyl N-substituted carbamates Eur. J. Med. Chem. 33 1998 985 990
13. A. Ranise, F. Bondavalli, P. Schenone, M. Angrisani, M. Lisa, R. Marrazzo, and E. Marmo Ureas and amides derived from N-(5-norbornen-2-ylmethyl) bornan-2-exo-amine with antiarrhythmic and other activities Farmaco 43 1988 79 89
14. G.W. Cambridge, J.F. Parsons, and R. Safford R. Budden D.K. Detweiler G. Zbinden The Rat Electrocardiogram in Pharmacology and Toxicology 1981 Pergamon Press Oxford, New York, Toronto 135 138
15. L. Szekeres, and G. Papp J. Schmier O. Eichler Handbook of Experimental Pharmacology 1975 Springer-Verlag Berlin, Heidelberg, New York
16. M.J. Walker, M.J. Curtis, D.J. Hearse, R.W. Campbell, M.J. Janse, D.M. Yellon, S.M. Cobbe, S.J. Coker, J.B. Harness, D.W. Harron, A.J. Higgins, D.G. Julian, M.J. Lab, A.S. Manning, B.J. Northover, J.R. Parratt, R.A. Riemersma, E. Riva, D.C. Russel, D.J. Sheridan, E. Winslow, and B. Woodward The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusion Cardiovasc. Res. 22 1988 447 455
17. J.T. Litchfield, and F. Wilcoxon A simplified method of evaluating dose-effect experiments J. Pharmacol. Exp. Ther. 96 1949 99 113
18. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
19. CAChe Work System Pro Version 5.04.
20. 1-adrenoceptors in the rat cortex Eur. J. Pharmacol. 119 1985 113 116
21. L.C. Hool, L.M. Oleksa, and R.D. Harvey Role of G proteins in alpha1-adrenergic inhibition of the beta-adrenergically activated chloride current in cardiac myocytes Mol. Pharmacol. 51 1997 853 860
22. M.R. Boyett, S.M. Harrison, N.C. Janvier, S.O. McMorn, J.M. Owen, and Z. Shui A list of vertebrate cardiac ionic currents nomenclature, properties, function and cloned equivalents Cardiovasc. Res. 32 1996 455 481
23. E. Carmeliet Cardiac ionic currents and acute ischemia: from channels to arrhytmias Physiol. Rev. 79 1999 917 1017
24. R.J. Hariman, J.A.C. Gomes, and N. El-Sherif Catecholamine-dependent atrioventricular nodal reentrant tachycardia Circulation 67 1983 681 686
25. 1 Adrenoceptor antagonists. Pharmacophore-based design, synthesis, and biological evaluation of new imidazo-, benzimidazo-, and indoloarylpiperazine derivatives J. Med. Chem. 45 2002 3603 3611
26. 1 adrenergic receptor subtypes, J. Comp.- Aid. Mol. Design 10 1996 545 557
27. 1 adrenoceptor antagonists Bioorg. Med. Chem. 11 2003 1065 1078
28. 1-adrenergic receptor antagonists Wiad. Chem. 57 2003 267 288
29. 1-Adrenoceptor antagonists. Rational design, synthesis and biological evaluation of new trazodone-like compounds Bioorg. Med. Chem. Lett. 12 2002 437 440
30. 1-Adrenoceptor antagonists. 5. Pyridazinone-arylpiperazines. Probing the influence on affinity and selectivity of both ortho-alkoxy groups at the arylpiperazine moiety and cyclic substituents at the pyridazinone nucleus Bioorg. Med. Chem. Lett. 13 2003 171 173
31. 2A receptors Bioorg. Med. Chem. Lett. 13 2003 175 178
32. 1 adrenoceptors Curr. Med. Chem. 8 2001 607 625
33. 1-adrenergic receptors Curr. Med. Chem. 9 2002 1303 1321
34. 1 adrenoceptor antagonists J. Med. Chem. 44 2001 2403 2410
35. 2-adrenoceptors J. Med. Chem. 44 2001 2118 2132
36. 1-adrenoceptor antagonists Bioorg. Med. Chem. 10 2002 361 369
37. 1-Adrenoceptor antagonists. 6. Structural optimization of pyridazinone-arylpiperazines. Study of the influence on affinity and selectivity of cyclic substituents at the pyridazinone ring and alkoxy groups at the arylpiperazine moiety J. Med. Chem. 46 2003 3555 3558
38. T.W. Lameris, S. de Zeeuw, A. Gooitzen, F. Boomsma, D.J. Duncker, P.D. Verdouw, A.J. Man in't Vel, and A.H. van den Meiracker Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo Circulation 101 2000 2645 2650